Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical ...
BMJ Global Health

Integration of azithromycin mass administration to 1–11-month-old children into an existing health platform to reduce child mortality: a cluster-randomised trial in Burki…

Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce childhood mortality; however, more ...

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Applic ...
BMJ Open

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) trial: a protocol for a pragmatic randomised study of diverticulitis treatment in the USA

Introduction Each year, millions of people experience recurrent diverticulitis episodes. Elective sigmoid colon resection reduces the risk of recurrence, but The American Society of Colon and Rectal ...
Ministry of Testing

Back to the basics: Rethinking how we use AI in testing

A simple rule of thumb: In general, AI is best reserved for well-defined, repetitive tasks. This includes anything that ...
Le Lézard

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity ...

Johnson & Johnson today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 ...

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval o…

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
TipRanks on MSN

Nova Minerals says Pakistani antimony discussions remain exploratory in nature

The company said, “Nova Minerals (NVA) has become aware of media articles speculating on the Company’s arrangements regarding the potential ...
Nature

Reviews & Analysis

A ‘photonic skin’ with controllable colour and texture brings materials science a step closer to the adaptive camouflage found in nature. A meta-analysis of 168 studies covering more than 11 million ...

DelveInsight Business Research, LLP: Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...
BMJ Open

Exploring recovery from anorexia in autistic adults: a qualitative study

Objectives To examine the barriers and facilitators of anorexia nervosa (AN) recovery in adults with autism. Design Qualitative study using semi-structured interviews with autistic adults who ...